title: Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation.
abstract: The effects of GM-/G-CSF and darbepoetin-alpha on stem cell mobilization were investigated. From February 2005 to March 2007, 30 allogeneic sibling donors were randomly assigned to a G-CSF group (5 microg/kg/day for 5-7 days) or triple group (GM-CSF 10 microg/kg/day on 1st and 2nd day, G-CSF 5 microg/kg/day for 5-7 days, and darbepoetin-alpha 40 mg on 1st day). The MNCs and CD34(+) cells were not different between the two groups, although the doses (x10(8)/kg of recipient body weight) of CD3(+) cells (3.64 +/- 1.75 vs. 2.63 +/- 1.36, P = 0.089) and CD8(+) cells (1.07 +/- 0.53 vs. 0.60 +/- 0.30, P = 0.006) were lower in the triple group. The engraftments, frequency of RBC transfusions, and hemoglobin recovery were not different between the two groups. The cumulative incidence of overall and Grades II-IV aGVHD was 64.3% vs. 61.1% and 25.9% vs. 27.1% in the G-CSF and triple regimen group, respectively, whereas the cumulative incidence of cGVHD was 20.8 +/- 1.3% and 24.4 +/- 1.7%, respectively. In conclusion, the triple regimen did not seem to be superior to G-CSF alone in terms of the CD34+ cell dose, hemoglobin recovery, and GVHD. However, the CD8+ cell count was significantly lower in the triple regimen group. The role of a lower CD8+ cell count in the graft may need to be elucidated in the future.
authors.affiliation: Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea.
authors.forename: Shi Nae
authors.initials: SN
authors.lastname: Kim
authors.forename: Joon Ho
authors.initials: JH
authors.lastname: Moon
authors.forename: Jong Gwang
authors.initials: JG
authors.lastname: Kim
authors.forename: Yee Soo
authors.initials: YS
authors.lastname: Chae
authors.forename: Yoon Young
authors.initials: YY
authors.lastname: Cho
authors.forename: Soo Jung
authors.initials: SJ
authors.lastname: Lee
authors.forename: Yun Jeong
authors.initials: YJ
authors.lastname: Kim
authors.forename: Yoo Jin
authors.initials: YJ
authors.lastname: Lee
authors.forename: Jang Soo
authors.initials: JS
authors.lastname: Suh
authors.forename: Kun Soo
authors.initials: KS
authors.lastname: Lee
authors.forename: Sang Kyun
authors.initials: SK
authors.lastname: Sohn
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000068256:Darbepoetin alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D000078224:Lenograstim; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage; D020127:Recovery of Function; D013234:Stem Cells / Q000166:cytology*; D014184:Transplantation, Homologous
chemical_list: D000276:Adjuvants, Immunologic; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068256:Darbepoetin alfa; C081222:sargramostim; D000078224:Lenograstim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor